Mitochondrial Energy Metabolism and Thyroid Cancers

Overview

Journal Endocrinol Metab (Seoul)

Specialty Endocrinology

Date 2015 Jul 22

PMID 26194071

Citations 6

Authors

Junguee Lee

Joon Young Chang

Yea Eun Kang

Shinae Yi

Min Hee Lee

Kyong Hye Joung

Kun Soon Kim

Minho Shong

Affiliations

Soon will be listed here.

Abstract

Primary thyroid cancers including papillary, follicular, poorly differentiated, and anaplastic carcinomas show substantial differences in biological and clinical behaviors. Even in the same pathological type, there is wide variability in the clinical course of disease progression. The molecular carcinogenesis of thyroid cancer has advanced tremendously in the last decade. However, specific inhibition of oncogenic pathways did not provide a significant survival benefit in advanced progressive thyroid cancer that is resistant to radioactive iodine therapy. Accumulating evidence clearly shows that cellular energy metabolism, which is controlled by oncogenes and other tumor-related factors, is a critical factor determining the clinical phenotypes of cancer. However, the role and nature of energy metabolism in thyroid cancer remain unclear. In this article, we discuss the role of cellular energy metabolism, particularly mitochondrial energy metabolism, in thyroid cancer. Determining the molecular nature of metabolic remodeling in thyroid cancer may provide new biomarkers and therapeutic targets that may be useful in the management of refractory thyroid cancers.

Citing Articles

Exploring the clinical utility of DPP-IV and SGLT2 inhibitors in papillary thyroid cancer: a literature review.

Buczynska A, Kosciuszko M, Kretowski A, Poplawska-Kita A Front Pharmacol. 2024; 15:1323083.

PMID: 38292938 PMC: 10824900. DOI: 10.3389/fphar.2024.1323083.

Development of Metabolic Synthetic Lethality and Its Implications for Thyroid Cancer.

Ju S, Lee S, Kang Y, Shong M Endocrinol Metab (Seoul). 2022; 37(1):53-61.

PMID: 35255601 PMC: 8901971. DOI: 10.3803/EnM.2022.1402.

Transcriptomic and Genetic Associations between Alzheimer's Disease, Parkinson's Disease, and Cancer.

Fores-Martos J, Boullosa C, Rodrigo-Dominguez D, Sanchez-Valle J, Suay-Garcia B, Climent J Cancers (Basel). 2021; 13(12).

PMID: 34203763 PMC: 8232649. DOI: 10.3390/cancers13122990.

Clinical Significance of the D-Loop Gene Mutation in Mitochondrial DNA in Laryngeal Cancer.

Wang L, Cheng H, Zhou Y, Ma M Onco Targets Ther. 2021; 14:3461-3466.

PMID: 34079291 PMC: 8165653. DOI: 10.2147/OTT.S304836.

Atovaquone enhances doxorubicin's efficacy via inhibiting mitochondrial respiration and STAT3 in aggressive thyroid cancer.

Lv Z, Yan X, Lu L, Su C, He Y J Bioenerg Biomembr. 2018; 50(4):263-270.

PMID: 29687367 DOI: 10.1007/s10863-018-9755-y.

References

Sosonkina N, Starenki D, Park J . The Role of STAT3 in Thyroid Cancer. Cancers (Basel). 2014; 6(1):526-44. PMC: 3980610. DOI: 10.3390/cancers6010526. View

Rasola A, Sciacovelli M, Chiara F, Pantic B, Brusilow W, Bernardi P . Activation of mitochondrial ERK protects cancer cells from death through inhibition of the permeability transition. Proc Natl Acad Sci U S A. 2010; 107(2):726-31. PMC: 2818893. DOI: 10.1073/pnas.0912742107. View

Kim Y, Byun H, Won M, Park K, Kim J, Choi B . Modulatory role of phospholipase D in the activation of signal transducer and activator of transcription (STAT)-3 by thyroid oncogenic kinase RET/PTC. BMC Cancer. 2008; 8:144. PMC: 2412888. DOI: 10.1186/1471-2407-8-144. View

Zhu Z, Gandhi M, Nikiforova M, Fischer A, Nikiforov Y . Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol. 2003; 120(1):71-7. DOI: 10.1309/ND8D-9LAJ-TRCT-G6QD. View

Veeriah S, Taylor B, Meng S, Fang F, Yilmaz E, Vivanco I . Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet. 2009; 42(1):77-82. PMC: 4002225. DOI: 10.1038/ng.491. View

Baris O, Savagner F, Nasser V, Loriod B, Granjeaud S, Guyetant S . Transcriptional profiling reveals coordinated up-regulation of oxidative metabolism genes in thyroid oncocytic tumors. J Clin Endocrinol Metab. 2004; 89(2):994-1005. DOI: 10.1210/jc.2003-031238. View

Suh J, Song J, Kim D, Kim H, Chung H, Hwang J . Regulation of the phosphatidylinositol 3-kinase, Akt/protein kinase B, FRAP/mammalian target of rapamycin, and ribosomal S6 kinase 1 signaling pathways by thyroid-stimulating hormone (TSH) and stimulating type TSH receptor antibodies in the thyroid.... J Biol Chem. 2003; 278(24):21960-71. DOI: 10.1074/jbc.M300805200. View

Abubaker J, Jehan Z, Bavi P, Sultana M, Al-Harbi S, Ibrahim M . Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab. 2007; 93(2):611-8. DOI: 10.1210/jc.2007-1717. View

Bos R, Zhong H, Hanrahan C, Mommers E, Semenza G, Pinedo H . Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst. 2001; 93(4):309-14. DOI: 10.1093/jnci/93.4.309. View

10.

Galli S, Jahn O, Hitt R, Hesse D, Opitz L, Plessmann U . A new paradigm for MAPK: structural interactions of hERK1 with mitochondria in HeLa cells. PLoS One. 2009; 4(10):e7541. PMC: 2760858. DOI: 10.1371/journal.pone.0007541. View

11.

Garcia-Rostan G, Costa A, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem M . Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res. 2005; 65(22):10199-207. DOI: 10.1158/0008-5472.CAN-04-4259. View

12.

Cox A, Winterbourn C, Hampton M . Mitochondrial peroxiredoxin involvement in antioxidant defence and redox signalling. Biochem J. 2009; 425(2):313-25. DOI: 10.1042/BJ20091541. View

13.

Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry J, De Micco C . Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab. 2003; 88(6):2745-52. DOI: 10.1210/jc.2002-021186. View

14.

Jose C, Bellance N, Rossignol R . Choosing between glycolysis and oxidative phosphorylation: a tumor's dilemma?. Biochim Biophys Acta. 2010; 1807(6):552-61. DOI: 10.1016/j.bbabio.2010.10.012. View

15.

Azad M, Chen Y, Gibson S . Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. Antioxid Redox Signal. 2008; 11(4):777-90. DOI: 10.1089/ars.2008.2270. View

16.

Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K . Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab. 2008; 93(8):3106-16. DOI: 10.1210/jc.2008-0273. View

17.

Tan C, de Noronha R, Roecker A, Pyrzynska B, Khwaja F, Zhang Z . Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res. 2005; 65(2):605-12. View

18.

Volante M, Rapa I, Gandhi M, Bussolati G, Giachino D, Papotti M . RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab. 2009; 94(12):4735-41. DOI: 10.1210/jc.2009-1233. View

19.

Kim D, Chung H, Park K, Hwang J, Jo Y, Chung J . Tumor suppressor LKB1 inhibits activation of signal transducer and activator of transcription 3 (STAT3) by thyroid oncogenic tyrosine kinase rearranged in transformation (RET)/papillary thyroid carcinoma (PTC). Mol Endocrinol. 2007; 21(12):3039-49. DOI: 10.1210/me.2007-0269. View

20.

Rustin P . Mitochondria, from cell death to proliferation. Nat Genet. 2002; 30(4):352-3. DOI: 10.1038/ng0402-352. View